Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Forman

Showing results (251-260 of 500) with videos related to

Pageof 50
Sort By:
Science Translational Medicine|September 4, 2020
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumorsAnthony K Park, Yuman Fong, Sang-In Kim, et al.
Blood Advances|September 7, 2021
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaTanya Siddiqi, Xiuli Wang, M Suzette Blanchard, et al.
British Journal of Haematology|April 27, 2011
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trialGeorge Somlo, Ashkan Lashkari, William Bellamy, et al.
Blood|December 15, 2005
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapyLisa Marie Serrano, Timothy Pfeiffer, Simon Olivares, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2002
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II studyBorje S Andersson, Ashwin Kashyap, Victor Gian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemiaAnthony S Stein, Joycelynne M Palmer, Margaret R O'Donnell, et al.
Cancer|April 5, 2024
Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphomaSmith Giri, Christian Harmon, Wendy Landier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?Amrita Krishnan, Auayporn Nademanee, Henry Fung, et al.
Blood|July 2, 2002
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialMary E D Flowers, Pablo M Parker, Laura J Johnston, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantationOlga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
Pageof 50

Showing results (251-260 of 500) with videos related to

Sort By:
Pageof 50
Science Translational Medicine|September 4, 2020
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumorsAnthony K Park, Yuman Fong, Sang-In Kim, et al.
Blood Advances|September 7, 2021
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaTanya Siddiqi, Xiuli Wang, M Suzette Blanchard, et al.
British Journal of Haematology|April 27, 2011
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trialGeorge Somlo, Ashkan Lashkari, William Bellamy, et al.
Blood|December 15, 2005
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapyLisa Marie Serrano, Timothy Pfeiffer, Simon Olivares, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2002
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II studyBorje S Andersson, Ashwin Kashyap, Victor Gian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemiaAnthony S Stein, Joycelynne M Palmer, Margaret R O'Donnell, et al.
Cancer|April 5, 2024
Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphomaSmith Giri, Christian Harmon, Wendy Landier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?Amrita Krishnan, Auayporn Nademanee, Henry Fung, et al.
Blood|July 2, 2002
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialMary E D Flowers, Pablo M Parker, Laura J Johnston, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantationOlga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
Pageof 50